转移性 Merkel 细胞癌对纳武利尤单抗的反应。
Metastatic Merkel cell carcinoma response to nivolumab.
机构信息
University of Michigan Medical School, Ann Arbor, MI USA.
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, C451 Med Inn, 1500 East Medical Center Drive, Ann Arbor, MI 48109 USA.
出版信息
J Immunother Cancer. 2016 Nov 15;4:79. doi: 10.1186/s40425-016-0186-1. eCollection 2016.
BACKGROUND
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis as a likely contributor to immune evasion in MCC.
CASE PRESENTATION
We report a case of a patient with metastatic MCC with a significant and durable response to nivolumab, a humanized IgG4 monoclonal anti-PD-1 antibody.
CONCLUSION
Immunotherapy with PD-1/PD-L1 inhibitors has become a rational and promising treatment option for MCC in the advanced or metastatic disease. Clinical trials are currently in progress to further evaluate these novel therapeutic agents.
背景
默克尔细胞癌（MCC）是一种侵袭性皮肤神经内分泌恶性肿瘤，治疗选择有限。有几项证据表明，程序性死亡受体 1/程序性死亡配体 1（PD-1/PD-L1）轴可能是 MCC 免疫逃逸的原因之一。
病例介绍
我们报告了一例转移性 MCC 患者，其对 nivolumab（一种人源化 IgG4 单克隆抗 PD-1 抗体）有显著且持久的反应。
结论
PD-1/PD-L1 抑制剂的免疫治疗已成为晚期或转移性 MCC 的一种合理且有前途的治疗选择。目前正在进行临床试验，以进一步评估这些新型治疗药物。
Zotero 插件